Union Korea Pharm Calls EGM to Appoint New Directors from Bukwang Pharmaceutical and Remove Existing Management
Background of EGM call: Union Korea Pharm has convened an extraordinary general meeting on July 21, 2026, with Bukwang Pharmaceutical as the acquirer, proposing the appointment of four new directors and the removal of seven existing directors.
New director candidates: Inside directors include Seong Gwang-hyun and Kim Sung-soo, both vice presidents from Bukwang Pharmaceutical; outside directors include Lim Jung-soo, professor at Yonsei University, and Min Byung-hwan, advisor at Hyosung TNS, all recommended by Bukwang.
Removal of existing management: The agenda includes dismissal of CEO Jeong Geun-ho and six other current registered directors, signaling a change in control.
[AI Summary]The acquisition by Bukwang Pharmaceutical is materializing with a complete board replacement. Short-term management vacuum risks exist, but long-term normalization and synergy creation are expected through Bukwang's resources and expertise. No capital changes or dividends are involved; shareholder value hinges on operational efficiency improvements.